comparemela.com

Latest Breaking News On - Taacr - Page 1 : comparemela.com

Toxicities Hinder Potential Efficacy of Ceritinib/Trametinib in Pretreated Advanced Melanoma

Zeynep Eroglu, MD, discusses how findings from a phase 1/2 study of ceritinib and trametinib could help inform future research in melanoma.

Zeynep erogluKeiran smalleyMoffitt cancer centerDepartment of oncologic sciencesCutaneous oncologyOncologic sciencesSouth florida morsani collegeCeritinib and trametinib

Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC

Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.

North carolinaUnited statesDuke universityJameel muzaffarDuke cancer institute in durhamDuke university school of medicineDepartment of medicineDuke university schoolDuke cancer instituteHead and neck squamous cell carcinoma

Proteogenomic Signatures Shed Light on Prostate Cancer Recurrence Risk in Select Ancestries

A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.

United statesSouth koreaCara schaferProstate disease researchDepartment of surgeryUniformed services university of the health sciencesHenrym jackson foundationResearch networkJohnp murtha cancer centerWalter reed national military medical centerUniformed services universityHealth sciencesApplied proteogenomic organizational learningCancer centerWalter reed national military medicalShyh han tan

Mirvetuximab Soravtansine Plus Pembrolizumab Makes a Splash in pMMR/MSS FRalpha+ Endometrial Cancer

Mirvetuximab soravtansine plus pembrolizumab in patients with recurrent or persistent, FRalpha-positive, pMMR/MSS serous endometrial cancer, according to findings from a phase 2 trial.

United statesRebeccal porterGynecologic oncology programDana farber cancer instituteDana farber cancer institutePmmr mss serous endometrial cancerPhase 2 trial nct03835819Mirvetuximab soravtansine elahere and pembrolizumab keytruda

AZD1390 Demonstrates Initial Safety, May Enhance Radiotherapy Efficacy in Glioblastoma

Early safety and efficacy data seen with AZD1390 in a phase 1 study indicate it's potential utility as a radiosensitizing treatment in glioblastoma.

Jonathant yangMemorial sloan kettering cancer center

vimarsana © 2020. All Rights Reserved.